Skip to main content

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Tempero, MA; Malafa, MP; Al-Hawary, M; Asbun, H; Bain, A; Behrman, SW; Benson, AB; Binder, E; Cardin, DB; Cha, C; Chiorean, EG; Chung, V ...
Published in: J Natl Compr Canc Netw
August 2017

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2017

Volume

15

Issue

8

Start / End Page

1028 / 1061

Location

United States

Related Subject Headings

  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Humans
  • Disease Management
  • Combined Modality Therapy
  • Clinical Decision-Making
  • Adenocarcinoma
  • 4203 Health services and systems
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S. W., … Darlow, S. (2017). Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(8), 1028–1061. https://doi.org/10.6004/jnccn.2017.0131
Tempero, Margaret A., Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson, et al. “Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 15, no. 8 (August 2017): 1028–61. https://doi.org/10.6004/jnccn.2017.0131.
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug;15(8):1028–61.
Tempero, Margaret A., et al. “Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 15, no. 8, Aug. 2017, pp. 1028–61. Pubmed, doi:10.6004/jnccn.2017.0131.
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O’Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug;15(8):1028–1061.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2017

Volume

15

Issue

8

Start / End Page

1028 / 1061

Location

United States

Related Subject Headings

  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Humans
  • Disease Management
  • Combined Modality Therapy
  • Clinical Decision-Making
  • Adenocarcinoma
  • 4203 Health services and systems